explore -WSS

explore

author：comprehensive 2025-10-01 14:19:59 - browse：79

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The explosion of genetic testing requires a new approach

Wikipedia

WSS

Hospital price transparency does save money, advocate argues

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

FDA warns J&J's Abiomed: We will regulate your software

Novo: Oral version of Ozempic leads to 15% weight loss

Eli Lilly expects to double planned employment in Boston center

hotspot

explore

explore

Virginia high school admissions case could be legal follow

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Medicare details structure of new drug price negotiation program

STAT Readout Newsletter: Today's biggest biotech updates

The high cost of giving birth even with insurance

Pharmacists can make shortage drugs, but at what cost?

At least 13 dead in Texas as scorching temps continue

Solve the antibiotic resistance crisis with preventive drugs

Drug repurposing or repositioning? The language matters

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

entertainment

STAT Summit: Biotech founders on deal

The explosion of genetic testing requires a new approach

The EU Joint Clinical Assessment needs to live up to its promise

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Biogen nominates mother of director’s child to replace him on board

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Wikipedia

focus

explore

knowledge